SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Stemline Therapeutics, Inc.' Lead Clinical Candidate, SL-401, Induces Another Complete Response in a Patient with a Drug-Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm